Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramAnnals of oncology, 2018-02, Vol.29 (2), p.405-417 [Peer Reviewed Journal]2017 European Society for Medical Oncology ;The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. 2017 ;The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;ISSN: 1569-8041 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdx651 ;PMID: 29092024Full text available |
|
2 |
Material Type: Article
|
Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designsOncogene, 2016-04, Vol.35 (14), p.1743-1749 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Apr 7, 2016 ;Macmillan Publishers Limited 2016. ;ISSN: 0950-9232 ;EISSN: 1476-5594 ;DOI: 10.1038/onc.2015.249 ;PMID: 26119941 ;CODEN: ONCNESFull text available |
|
3 |
Material Type: Article
|
The AURORA initiative for metastatic breast cancerBritish journal of cancer, 2014-11, Vol.111 (10), p.1881-1887 [Peer Reviewed Journal]2015 INIST-CNRS ;Copyright Nature Publishing Group Nov 11, 2014 ;Copyright © 2014 Cancer Research UK 2014 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2014.341 ;PMID: 25225904 ;CODEN: BJCAAIFull text available |
|
4 |
Material Type: Article
|
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerThe New England journal of medicine, 2016-08, Vol.375 (8), p.717-729 [Peer Reviewed Journal]Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1602253 ;PMID: 27557300Full text available |
|
5 |
Material Type: Article
|
90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)Annals of oncology, 2022-05, Vol.33, p.S162-S163 [Peer Reviewed Journal]2022 European Society for Medical Oncology ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2022.03.105Full text available |
|
6 |
Material Type: Article
|
295P Climate change impact and sustainability: A survey of Breast International Group (BIG) membersESMO open, 2024-05, Vol.9 [Peer Reviewed Journal]2024 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2024.103352Full text available |
|
7 |
Material Type: Article
|
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancerAnnals of oncology, 2019-10, Vol.30, p.v97 [Peer Reviewed Journal]ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz240.112Full text available |
|
8 |
Material Type: Article
|
289TiP - ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancerAnnals of oncology, 2019-10, Vol.30, p.v97-v97 [Peer Reviewed Journal]2019 European Society for Medical Oncology ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz240.112Full text available |
|
9 |
Material Type: Article
|
Abstract OT1-03-05: A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously- treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study)Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-05-OT1-03-05 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS15-OT1-03-05Full text available |
|
10 |
Material Type: Article
|
Abstract P6-11-16: PYTHIA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancerCancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-11-16 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS16-P6-11-16Full text available |
|
11 |
Material Type: Article
|
Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancerCancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-05-08-OT3-05-08 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS17-OT3-05-08Full text available |
|
12 |
Material Type: Article
|
Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancerCancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-05-02-OT3-05-02 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS18-OT3-05-02Full text available |
|
13 |
Material Type: Article
|
PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancerAnnals of oncology, 2017-09, Vol.28, p.v66-v66 [Peer Reviewed Journal]2017 European Society for Medical Oncology ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdx362.064Full text available |
|
14 |
Material Type: Article
|
Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trialCancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-14-01 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS16-P5-14-01Full text available |
|
15 |
Material Type: Article
|
Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD7-12-PD7-12 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS17-PD7-12Full text available |
|
16 |
Material Type: Article
|
Abstract P5-23-01: Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registryCancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-23-01 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS17-P5-23-01Full text available |
|
17 |
Material Type: Article
|
Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancerCancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-21-OT1-03-21 [Peer Reviewed Journal]ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/1538-7445.SABCS15-OT1-03-21Full text available |
|
18 |
Material Type: Article
|
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 1533-4406 ;EISSN: 1533-4406Full text available |
|
19 |
Material Type: Article
|
289TiPALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancerAnnals of oncology, 2019-10, Vol.30 (Supplement_5) [Peer Reviewed Journal]European Society for Medical Oncology 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz240.112Full text available |
|
20 |
Material Type: Article
|
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramAnnals of Oncology, 2018-02, Vol.29 (2), p.405-417open access ;DOI: 10.1093/annonc/mdx651Digital Resources/Online E-Resources |